Argenx SE, a leading biotechnology company, has reported impressive half-year financial results, exceeding market expectations with a GAAP EPS of $6.32 and revenue of $1.74 billion.

Argenx SE is preparing to release its financial results, highlighting the company’s ongoing commitment to advancing healthcare through innovative antibody-based therapies in the biotechnology industry.

Argenx SE, a biotechnology company, is making significant strides in treating severe autoimmune diseases and cancer with its innovative antibody-based therapies, including a promising candidate set to enter a registrational trial for Congenital Myas…

Argenx SE has secured European Commission approval for its innovative VYVGART subcutaneous injection, marking a significant milestone in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Argenx SE’s treatment VYVGART has received a positive opinion from the European CHMP, paving the way for potential approval and marking a significant milestone in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).